IL6 and breast carcinoma: Moreover, an in vivo tumorigenesis assay in NSG mice revealed that, unlike estrogen-dependent MCF7_Cont cells, MCF7_TG2 breast cancer cells obtained tumorigenic capability in vivo without the addition of exogenous estrogen, which were reduced in the presence of blocking anti-IL-6 or anti-IL-1β antibodies or the TG2 inhibitor cysteamine (CyM) (Fig. 4c).